Načítá se...
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
The physiological decrease in vaginal estrogens is accountable for the emergence of vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria. The repercussion of these symptoms on quality of life often ma...
Uloženo v:
| Vydáno v: | Int J Womens Health |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089832/ https://ncbi.nlm.nih.gov/pubmed/27822125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S110035 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|